SK Biopharmaceuticals faces partial clinical hold for opacalim epilepsy drug candidate
AI Summary- SK Biopharmaceuticals received a partial clinical hold on opacalim’s Phase 2/3 trials.
- More than 1,200 people have received opacalim, with no directly linked clinical adverse events identified.
- RISE3 remains on track for second-half 2026 topline results, while RISE2 stopped new enrollment.